Hemab Therapeutics Holdings Past Earnings Performance

Past criteria checks 0/6

Hemab Therapeutics Holdings's earnings have been declining at an average annual rate of -35.9%, while the Biotechs industry saw earnings growing at 34.1% annually.

Key information

-35.91%

Earnings growth rate

-35.91%

EPS growth rate

Biotechs Industry Growth	17.04%
Revenue growth rate	n/a
Return on equity	-44.13%
Net Margin	n/a
Last Earnings Update	31 Mar 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jul 15

Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts

Summary Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029, supporting multiple clinical catalysts across sutacimig, HMB-002, and preclinical HMB-003. Lead asset sutacimig shows strong Phase 2 efficacy and FDA-aligned Phase 3 dosing, while HMB-002 and HMB-003 broaden addressable markets. I am bullish as Hemab's pipeline offers multiple shots on goal, favorable market positioning, and compelling orphan/large market expansion potential. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Hemab Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:COAG Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 26	0	-71	12	65
31 Dec 25	0	-64	10	60

Quality Earnings: COAG is currently unprofitable.

Growing Profit Margin: COAG is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Unable to establish if COAG's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare COAG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: COAG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (67.9%).

Return on Equity

High ROE: COAG has a negative Return on Equity (-44.13%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/09 19:41
End of Day Share Price	2026/08/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemab Therapeutics Holdings, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Cory Kasimov	Evercore ISI
Richard J. Law	Goldman Sachs
Emily Bodnar	H.C. Wainwright & Co.